Abstract

Emerging treatment options for extraintestinal manifestations in IBD

Gut. 2020 Aug 26;gutjnl-2020-322129. doi: 10.1136/gutjnl-2020-322129.Online ahead of print.

Thomas Greuter 1 2, Florian Rieder 3, Torsten Kucharzik 4, Laurent Peyrin-Biroulet 5, Alain M Schoepfer 6 7, David T Rubin 8, Stephan R Vavricka 1 9

 
     

Author information

  • 1Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland stephan.vavricka@usz.ch th_greuter@bluewin.ch.
  • 2Department of Internal Medicine, GZO - Zurich Regional Health Center, Wetzikon, Switzerland.
  • 3Division of Gastroenterology, Hepatology & Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, OH, United States.
  • 4Division of Gastroenterology and Hepatology, Klinikum Lueneburg, Lueneburg, Germany.
  • 5Inserm U954, Department of Hepato-Gastroenterology, University Hospital of Nancy, Université Henri Poincaré 1, Vandoeuvre-lès-Nancy, France.
  • 6Division of Gastroenterology and Hepatology, University Hospital Lausanne - CHUV, Lausanne, Switzerland.
  • 7University of Lausanne, Lausanne, Switzerland.
  • 8Inflammatory Bowel Disease Center, University of Chicago, Chicago, IL, United States.
  • 9Gastroenterology and Hepatology Center, Zurich, Switzerland.

Abstract

Extraintestinal manifestations (EIMs) are frequently observed in IBDs and contribute considerably to morbidity and mortality. They have long been considered a difficult to treat entity due to limited therapy options, but the increasing use of anti-tumour necrosis factors has dramatically changed the therapeutic approach to EIM in recent years. Newly emerging therapies such as JAK inhibitors and anti-interleukin 12/23 will further shape the available armamentarium. Clinicians dealing with EIMs in everyday IBD practice may be puzzled by the numerous available biological agents and small molecules, their efficacy for EIMs and their potential off-label indications. Current guidelines on EIMs in IBD do not include treatment algorithms to help practitioners in the treatment decision-making process. Herein, we summarise knowledge on emerging biological treatment options and small molecules for EIMs, highlight current research gaps, provide therapeutic algorithms for EIM management and shed light on future strategies in the context of IBD-related EIMs.

© Copyright 2013-2020 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.